In this article

NVO

Follow your favorite stocks CREATE FREE ACCOUNT

Novo Nordisk reported promising mid-stage results for its experimental drug amycretin in diabetes patients on Tuesday, sending its Denmark-listed shares up nearly 4% as investors bet on the company's bid to reclaim leadership in the weight-loss market.

The results come at a pivotal time for the Danish drugmaker, which a day earlier, reported disappointing results for semaglutide, the active ingredient in its blockbuster obesity drug Wegovy, in closely watched Alzheimer's trials, dashing hopes that GLP-1 drugs could break into a vast new market for the mind-wasting disease.

With semaglutide patents expiring around 2031-2032 and competition heating up, Novo is facing mounting pressure to prove its next wave of

See Full Page